Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- MGNX
- Price
- 1.31
- Stock movement down
- -0.05 (-3.36%)
- Company name
- MacroGenics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 91.02M
- Ent value
- 55.82M
- Price/Sales
- 0.64
- Price/Book
- 0.76
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -0.10%
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -48.88%
- 1 year return
- -59.44%
- 3 year return
- -31.65%
- 5 year return
- -44.10%
- 10 year return
- -26.56%
Last updated: 2025-09-15
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
DIVIDENDS
MGNX does not pay dividends or no data was received
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 0.64 |
| Price to Book | 0.76 |
| EV to Sales | 0.39 |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 63.21M |
| EPS (TTM) | -1.55 |
| FCF per share (TTM) | -0.98 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 141.33M |
| Gross profit (TTM) | 128.81M |
| Operating income (TTM) | -107.09M |
| Net income (TTM) | -97.62M |
| EPS (TTM) | -1.55 |
| EPS (1y forward) | -2.78 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 91.14% |
| Operating margin (TTM) | -75.78% |
| Profit margin (TTM) | -69.07% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 179.63M |
| Net receivables | 8.75M |
| Total current assets | 222.20M |
| Goodwill | 0.00 |
| Intangible assets | 0.00 |
| Property, plant and equipment | 41.11M |
| Total assets | 264.49M |
| Accounts payable | 6.61M |
| Short/Current long term debt | 34.10M |
| Total current liabilities | 59.31M |
| Total liabilities | 144.43M |
| Shareholder's equity | 120.07M |
| Net tangible assets | 0.00 |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -58.00M |
| Capital expenditures (TTM) | 3.71M |
| Free cash flow (TTM) | -61.71M |
| Dividends paid (TTM) | 59.00K |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | -81.30% |
| Return on Assets | -36.91% |
| Return on Invested Capital | -78.21% |
| Cash Return on Invested Capital | -49.44% |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 1.49 |
| Daily high | 1.49 |
| Daily low | 1.44 |
| Daily Volume | 305K |
| All-time high | 40.21 |
| 1y analyst estimate | 3.40 |
| Beta | 1.66 |
| EPS (TTM) | -1.55 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 11 Nov 2025 |
Downside potential
Loading...
Downside potential data
| MGNX | S&P500 | |
| Current price drop from All-time high | -96.42% | -1.46% |
| Highest price drop | -97.36% | -56.47% |
| Date of highest drop | 4 Apr 2025 | 9 Mar 2009 |
| Avg drop from high | -55.95% | -10.99% |
| Avg time to new high | 213 days | 12 days |
| Max time to new high | 2916 days | 1805 days |
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
COMPANY DETAILS
Marketcap
91.02M
Marketcap category
Small-cap
Description
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule for the treatment of solid tumors, which is in preclinical trials. It is also developing next generation T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
Employees
341
Website
Investor relations
-
SEC filings
CEO
Scott E. Koenig
Country
USA
City
Rockville
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
iO Charts is a Seeking Alpha partner
iO Charts is a Seeking Alpha partner
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
iO Charts is a Seeking Alpha partnerNext page